Divis Laboratories532488Quarterly results
Board approves September 2026 results; auditors' limited review report is unmodified
Board meeting of 07.11.2026 approved unaudited results for the quarter and half year ended 30 September 2026.
By ScoutQuest · · 2 min read
| Line item | Latest | Year ago | YoY | Prev qtr | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3676 | 2715 | +35.4% | 3080 | +19.4% |
| Total income | 3770 | 2860 | +31.8% | 3144 | +19.9% |
| Profit before tax | 1505 | 912 | +65% | 1180 | +27.5% |
| Profit after tax | 1127 | 689 | +63.6% | 902 | +24.9% |
| Total comprehensive income | 1129 | 692 | +63.2% | 904 | +24.9% |
| Basic EPS | 42.49 | 25.97 | +63.6% | 33.95 | +25.2% |
- Total income YoY growth
- +31.8% (year ago 2860)
- Profit after tax YoY growth
- 1127 latest, +63.6% (year ago 689)
- Period
- Quarter ended 30.09.2026
Auditor's review
Conclusion: Unmodified
Notes to the results
- Forex gain of 24 (Rs. in Crores) for the quarter ended 30.09.2026 (half year 17) is included in Other Income; forex losses are included in Other Expenses.
- The consolidated results include Divi's Laboratories Limited and its two subsidiaries - Divis Laboratories (USA) Inc. and Divi's Laboratories Europe AG.
The board of the company met on 07 November 2026 and approved its unaudited financial results for the quarter and half year ended 30 September 2026.
What the board approved
- Standalone unaudited financial results for the quarter and half year ended 30 September 2026, with the statutory auditors' limited review report.
- Consolidated unaudited financial results for the same period, with the statutory auditors' limited review report.
- A press release on the financial results.
- The meeting commenced at 10.30 Hrs and concluded at 11.40 Hrs.
Auditor's conclusion
Price Waterhouse Chartered Accountants LLP reviewed both statements and issued an unmodified report. In simple terms, nothing came to the auditors' attention that caused them to believe the statements were not prepared in line with the applicable accounting standards. The results are unaudited, were reviewed by the Audit Committee and approved by the board.
Standalone numbers (Rs. in Crores)
- Revenue from operations: 3647 for the quarter, 6621 for the half year.
- Total income: 3735 for the quarter, 6765 for the half year.
- Profit for the period: 1140 for the quarter, 2031 for the half year.
- Basic and diluted earnings per share: 42.97 for the quarter, 76.52 for the half year (face value Rs. 2/- per share).
Consolidated numbers (Rs. in Crores)
- Revenue from operations: 3676 for the quarter, 6756 for the half year.
- Total income: 3770 for the quarter, 6907 for the half year.
- Profit for the period: 1127 for the quarter, 2029 for the half year.
- Basic and diluted earnings per share: 42.49 for the quarter, 76.44 for the half year.
Other points from the notes
- The company, and the group, each operate as a single reportable business segment: manufacture of Active Pharmaceutical Ingredients, intermediates and nutraceutical ingredients.
- There are no discontinued operations; the reported profit represents continuing operations only.
- Forex gain of 27 for the quarter and 20 for the half year at standalone level, and 24 and 17 at consolidated level, is included in Other Income.
- Standalone cash flow for the half year shows 370 of net cash inflow from operating activities, 871 paid for property, plant and equipment, and 797 of dividend paid to shareholders (all Rs. in Crores).
How to read it
- This is a routine quarterly and half-yearly results announcement, with the auditors' review conclusion being unmodified.
- The update gives both standalone and consolidated figures, so you can see the core Indian business and the group including its overseas subsidiaries.
- Figures are in Rs. in Crores and are unaudited, so they are interim numbers reviewed by the auditors rather than a full-year audit.
₹2029 CrConsolidated Profit for the period - half year ended 30.09. (Rs. in Crores
Consolidated Profit for the period - quarter ended 30.09. (Rs. in Crores₹1127 Cr
Profit after tax, quarter902 (Rs. in Crores)
Also from Divis Laboratories
Audio recording of Q2 FY27 earnings call held November 07, 2026 uploaded on website
7 Nov 2026
Divis Labs shares saw profit booking after its post-results rally
3 Nov 2026
Divi's Laboratories to host Q2FY27 earnings conference call on November 07, 2026 at 14:00 hrs IST
2 Nov 2026
More numbers
- Standalone Revenue from operations - quarter ended 30.09.2026 (Rs. in Crores)3647
- Standalone Profit for the period - quarter ended 30.09.2026 (Rs. in Crores)1140
- Standalone Revenue from operations - half year ended 30.09.2026 (Rs. in Crores)6621
- Standalone Profit for the period - half year ended 30.09.2026 (Rs. in Crores)2031
- Consolidated Revenue from operations - half year ended 30.09.2026 (Rs. in Crores)6756
- Consolidated Profit for the period - half year ended 30.09.2026 (Rs. in Crores)2029
- Total income, latest quarter3770 (Rs. in Crores)
- Total income, year-ago quarter2860 (Rs. in Crores)
- Total income, previous quarter3144 (Rs. in Crores)
- Total comprehensive income, latest quarter1129 (Rs. in Crores)
- Total comprehensive income, year-ago quarter692 (Rs. in Crores)
- Total comprehensive income, previous quarter904 (Rs. in Crores)
- Profit after tax, latest quarter1127 (Rs. in Crores)
- Profit after tax, year-ago quarter689 (Rs. in Crores)
- Profit after tax, previous quarter902 (Rs. in Crores)
- Revenue from operations, latest quarter3676 (Rs. in Crores)
- Revenue from operations, year-ago quarter2715 (Rs. in Crores)
- Revenue from operations, previous quarter3080 (Rs. in Crores)
- Profit before tax, latest quarter1505 (Rs. in Crores)
- Profit before tax, year-ago quarter912 (Rs. in Crores)
- Profit before tax, previous quarter1180 (Rs. in Crores)
- Basic EPS, latest quarter42.49 (Rs. per share)
- Basic EPS, year-ago quarter25.97 (Rs. per share)
- Basic EPS, previous quarter33.95 (Rs. per share)
Source: BSE · 7 Nov 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.